Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Moderna (MRNA) Stock Is Up Today

February 18, 2025 at 14:22 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MRNA Cover Image

What Happened?

Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results. Despite this, Barclays seems to be exercising caution, downgrading the stock to equal weight from overweight earlier in the morning. The firm cited "policy risks, fewer clinical catalysts, and broader economic uncertainties that could limit its upside.".

Is now the time to buy Moderna? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Moderna’s shares are extremely volatile and have had 40 moves greater than 5% over the last year. But moves this big are rare even for Moderna and indicate this news significantly impacted the market’s perception of the business.

Moderna is down 15.1% since the beginning of the year, and at $35.69 per share, it is trading 78.6% below its 52-week high of $166.61 from May 2024. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $1,887.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article